Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
NCT ID: NCT00551954
Last Updated: 2013-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
NCT01167231
Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes
NCT00562133
Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects
NCT01946347
Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?
NCT00259168
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
NCT00118937
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
20 weeks of treatment with acarbose (100 mg t.i.d.)
acarbose
100 mg (tablets) t.i.d.
2
20 weeks of treatment with placebo (one tablet t.i.d.)
placebo
one tablet t.i.d.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
acarbose
100 mg (tablets) t.i.d.
placebo
one tablet t.i.d.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 2 diabetes (newly diagnosed)
* well glycemic control (HbA1c \</= 8.1)
* leucocyte count \> 6.2 or hs CrP \> 1
Exclusion Criteria
* type 1 diabetes
* previous treatment with antidiabetic drugs
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markolf Hanefeld, PhD
Role: PRINCIPAL_INVESTIGATOR
Center for Clinical Studies, Fiedlerstr. 34, 01307 Dresden, Germany
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AIDA a4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.